07035.
ABOUT MIDDLEBROOK PHARMACEUTICALS:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical
company focused on the development and commercialization of anti-infective
drug products that fulfill substantial unmet medical needs in the treatment
of infectious disease. The Company is developing anti-infective drugs based
on its novel biological finding that bacteria exposed to antibiotics in
front-loaded staccato bursts, or "pulses," are killed more efficiently and
effectively than those under standard treatment regimens. Based on this
finding, MiddleBrook has developed a proprietary, once-a-day pulsatile
delivery technology called PULSYS(R). The Company currently markets the
Keflex(R) brand of cephalexin and has received regulatory approval for
MOXATAG(TM) -- the first and only once-daily amoxicillin product approved
for marketing in the U.S. For more on MiddleBrook, please visit
http://www.middlebrookpharma.com.
'/>"/>SOURCE MiddleBrook Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 20082.
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million3.
Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds4.
BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 20085.
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients6.
Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 20087.
Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference8.
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing9.
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results10.
Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI11.
JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM)